



## Clinical Policy: Talimogene laherepvec (Imlygic)

Reference Number: LA.PHAR.542

Effective Date: 09.29.23

Last Review Date: ~~12.16.25~~02.03.25

Line of Business: Medicaid

[Coding Implications](#)

[Revision Log](#)

Formatted Table

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

**\*\*Please note: This policy is for medical benefit\*\***

### Description

Talimogene laherepvec (Imlygic®) is genetically modified oncolytic viral therapy.

### FDA Approved Indication(s)

Imlygic is indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery.

Limitation(s) of use: Imlygic has not been shown to improve overall survival or have an effect on visceral metastases.

### Policy/Criteria

*Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.*

It is the policy of Louisiana Healthcare Connections® that Imlygic is **medically necessary** when the following criteria are met:

#### I. Initial Approval Criteria

##### A. Melanoma (must meet all):

1. Diagnosis of unresectable, limited resectable, or metastatic melanoma;
2. Prescribed by or in consultation with an oncologist;
3. Age ≥ 18 years;
4. Prescribed in one of the following ways (a or b):
  - a. A single agent;
  - b. In combination with Yervoy®\* as subsequent therapy for metastatic or unresectable melanoma (*off-label*);  
*\*Prior authorization may be required for Yervoy*
5. Documentation of both the following (a and b):
  - a. Lesions are cutaneous, subcutaneous, or nodal;
  - b. Quantity and sizes of lesions;
6. Request meets one of the following (a or b):\*
  - a. Both of the following (i and ii):
    - i. For initial dose: Dose does not exceed 4 mL of 10<sup>6</sup> plaque-forming units (PFU)/mL (*see Appendix D*);

## CLINICAL POLICY

### Talimogene laherepvec

- ii. For all subsequent doses (starting 3 weeks after initial dose) and reinitiation:  
Dose does not exceed 4 mL of  $10^8$  PFU/mL every 2 weeks (*see Appendix D*);
- b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

*\*Prescribed regimen must be FDA-approved or recommended by NCCN*

**Approval duration: 6 months**

#### **B. Merkel Cell Carcinoma (off label) (must meet all):**

1. Diagnosis of Merkel cell carcinoma;
2. Prescribed by or in consultation with an oncologist;
3. Age  $\geq$  18 years;
4. Prescribed as a single agent;
5. One of the following (a or b):
  - a. Curative surgery or radiation therapy is not feasible;
  - b. Disease is metastatic;
6. Documentation of both the following (a and b):
  - a. Lesions are cutaneous, subcutaneous, or nodal;
  - b. Quantity and sizes of lesions;
7. Request meets one of the following (a or b):\*
  - a. Both of the following (i and ii):
    - i. For initial dose: Dose does not exceed 4 mL of  $10^6$  plaque-forming units (PFU)/mL (*see Appendix D*);
    - ii. For all subsequent doses (starting 3 weeks after initial dose) and reinitiation: Dose does not exceed 4 mL of  $10^8$  PFU/mL every 2 weeks (*see Appendix D*);
  - b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

*\*Prescribed regimen must be FDA-approved or recommended by NCCN*

**Approval duration: 6 months**

#### **B.C. Other diagnoses/indications (must meet 1 or 2):**

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to LA.PMN.255
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy ~~for the relevant line of business~~ LA.PMN.53.

## II. Continued Therapy

#### **A. ~~Melanoma~~ All Indications in Section I (must meet all):**

1. Currently receiving medication via Louisiana Healthcare Connections benefit, or documentation supports that member is currently receiving Imlygic for a covered indication and has received this medication for at least 30 days;

## CLINICAL POLICY

### Talimogene laherepvec

2. Member is responding positively to therapy;
3. Documentation of both the following (a and b):
  - a. New or remaining lesions are cutaneous, subcutaneous, or nodal;
  - b. Quantity and sizes of new or remaining lesions;
4. If request is for a dose increase, request meets one of the following (a or b):\*
  - a. New dose does not exceed 4 mL of 10<sup>8</sup> PFU/mL every 2 weeks (*see Appendix D*);
  - b. New dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

*\*Prescribed regimen must be FDA-approved or recommended by NCCN*

**Approval duration: 12 months**

#### **B. Other diagnoses/indications** (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to LA.PMN.255
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy ~~for the relevant line of business~~ LA.PMN.53.

#### **III. Diagnoses/Indications for which coverage is NOT authorized:**

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policy ~~ies~~ LA.PMN.53.

#### **IV. Appendices/General Information**

*Appendix A: Abbreviation/Acronym Key*

FDA: Food and Drug Administration

NCCN: National Comprehensive Cancer Network

PFU: plaque-forming units

*Appendix B: Therapeutic Alternatives*

*Not applicable*

*Appendix C: Contraindications/Boxed Warnings*

- Contraindication(s): immunocompromised patients, pregnancy
- Boxed warning(s): none

*Appendix D: Determination of Imlygic Injection Volume Based on Lesion Size*

Lesion Size (longest dimension)	Injection Volume
> 5 cm	up to 4 mL
> 2.5 cm to 5 cm	up to 2 mL
> 1.5 cm to 2.5 cm	up to 1 mL

Formatted: Indent: Left: 0.75"

## CLINICAL POLICY

### Talimogene laherepvec

Lesion Size (longest dimension)	Injection Volume
> 0.5 cm to 1.5 cm	up to 0.5 mL
≤ 0.5 cm	up to 0.1 mL

When lesions are clustered together, they should be injected together as a single lesion according to this table.

#### V. Dosage and Administration

Indication	Dosing Regimen	Maximum Dose
Melanoma	Recommended starting dose for injection into cutaneous, subcutaneous, and/or nodal lesions is up to 4 mL at a concentration of $10^6$ (1 million) PFU per mL, followed by up to 4 mL of $10^8$ (100 million) PFU/mL administered 3 weeks later; thereafter, subsequent doses (including reinitiation) of up to 4 mL of $10^8$ PFU/mL are administered every 2 weeks	4 mL at a concentration of $10^8$ PFU/mL per treatment (all lesions combined)

#### VI. Product Availability

Single-use vials:  $10^6$  (1 million) PFU/mL,  $10^8$  (100 million) PFU/mL

#### VII. References

1. Imlygic Prescribing Information. Thousand Oaks, CA: Amgen; ~~February 2023~~November 2024. Available at: <https://www.imlygic.com/>. Accessed May ~~23, 2024~~13, 2025.
2. National Comprehensive Cancer Network Drugs and Biologics Compendium. Available at: [https://www.nccn.org/professionals/drug\\_compendium/content/](https://www.nccn.org/professionals/drug_compendium/content/). Accessed May ~~23, 2024~~13, 2025.
3. National Comprehensive Cancer Network. Melanoma: Cutaneous Version 02.~~2024~~2025. Available at: [https://www.nccn.org/professionals/physician\\_gls/pdf/cutaneous\\_melanoma.pdf](https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf). Accessed May ~~23, 2024~~13, 2025.

#### Coding Implications

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

HCPSC Codes	Description
J9325	Injection, talimogene laherparepvec, per 1 million plaque forming units

Reviews, Revisions, and Approvals	Date	LDH Approval Date
Policy created	05.01.23	08.28.23

## CLINICAL POLICY

### Talimogene laherepvec

Reviews, Revisions, and Approvals	Date	LDH Approval Date
Annual review: updated dosing in initial approval criteria so that member meets both initial and subsequent dosing; added reinitiation dose in initial approval criteria to align with dosing section in prescriber information; references reviewed and updated.	04.05.24	07.10.24
Annual review: added criteria for metastatic melanoma and off label criteria for combination use with Yervoy per NCCN compendium; in continued therapy, clarified criteria to require documentation of the type, quantity, and size of new or remaining lesions; references reviewed and updated.	02.03.25	<u>05.19.25</u>
<u>Annual review: added off-label criteria for Merkel cell carcinoma per NCCN; references reviewed and updated</u>	<u>12.16.25</u>	

#### **Important Reminder**

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. LHCC makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions, and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable LHCC administrative policies and procedures.

This clinical policy is effective as of the date determined by LHCC. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. LHCC retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

## CLINICAL POLICY

### Talimogene laherepvec

This clinical policy does not constitute medical advice, medical treatment, or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom LHCC has no control or right of control. Providers are not agents or employees of LHCC.

This clinical policy is the property of LHCC. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members, and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

©2025 Louisiana Healthcare Connections. All rights reserved. All materials are exclusively owned by Louisiana Healthcare Connections and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Louisiana Healthcare Connections. You may not alter or remove any trademark, copyright or other notice contained herein. Louisiana Healthcare Connections is a registered trademark exclusively owned by Louisiana Healthcare Connections.